Skip to content
SENSEX81,250.32+0.42%NIFTY 5024,680.10+0.35%BANK NIFTY52,340.55-0.21%FIN NIFTY23,110.75+0.18%DOW JONES39,750.20-0.12%NASDAQ17,890.40+0.55%S&P 5005,460.30+0.29%GOLD71,500.00+0.65%SILVER84,200.00+1.10%USD/INR83.42-0.05%BITCOIN5,820,000.00+2.35%SENSEX81,250.32+0.42%NIFTY 5024,680.10+0.35%BANK NIFTY52,340.55-0.21%FIN NIFTY23,110.75+0.18%DOW JONES39,750.20-0.12%NASDAQ17,890.40+0.55%S&P 5005,460.30+0.29%GOLD71,500.00+0.65%SILVER84,200.00+1.10%USD/INR83.42-0.05%BITCOIN5,820,000.00+2.35%
Market News

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Business - Latest - Google News · September 4, 2026

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal  WSJNovartis, Ionis’ experimental heart drug misses key goal in closely watched trial  ReutersThe Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists  The New York TimesRoyalty Pharma expects modest return despite pelacarsen trial failure  in.investing.comNovartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial  Fierce Biotech

View original source →

More News

2026 Mahindra Scorpio N Launch Price Rs 13.69 Lakh To Rs 25.49 Lakh
Anthropic To Woo Investors With $30-Trillion Market Opportunity Ahead Of Mega IPO
Wai Wai bhujia under FSSAI scanner: Ajmer firm told to stop production, 32,000kg stock seized
OpenAI cuts off Cursor's AI models, deepening feud with Musk